For Del19 EGFR Mutation-Positive Lung Adenocarcinoma, Afatinib Improves Overall Survival

Share this content:

the Cancer Therapy Advisor take:

According to an analysis of two phase 3 studies published in the journal The Lancet Oncology, although afatinib did not improve overall survival among the overall population with EGFR mutation-positive lung adenocarcinoma in both studies, it did improve overall survival among those with del19 EGFR mutations.

For the two open-label, phase 3 LUX-Lung 3 and LUX-Lung 6 studies, researchers sought to investigate the effect of afatinib on overall survival among with EGFR mutation-positive lung adenocarcinoma.

Researchers enrolled 345 patients with previously untreated EGFR mutation-positive stage 3B or 4 lung adenocarcinoma in the LUX-Lung 3 study and randomly assigned them 2:1 to receive afatinib or pemetrexed plus cisplatin, and enrolled 364 patients in LUX-Lung 6 and randomly assigned them to receive afatinib or gemcitabine plus cisplatin.

Results showed that in LUX-Lung 3, the median overall survival was 28.2 months (95% CI: 24.6-33.6) in the afatinib group and 28.2 months (95% CI: 20.7-33.2) in the chemotherapy group (HR = 0.88; 95% CI: 0.66-1.17; P = 0.39).

In LUX-Lung 6, the median overall survival was 23.1 months (95% CI: 20.4-27.3) in the afatinib group and 23.5 months (95% CI: 18.0-25.6) in the chemotherapy group (HR = 0.93; 95% CI: 0.72-1.22; P = 0.61). In both studies, overall survival for those with del19 mutations was significantly longer in the afatinib group versus the chemotherapy group.

Ceritinib Demonstrates Strong Response in ALK-positive NSCLC
Afatinib did not improve overall survival among the overall population with EGFR mutation-positive lung adenocarcinoma.
The authors aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Although afatinib did not improve overall survival in the whole population of either trial, overall survival was improved with the drug for patients with del19 EGFR mutations.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs